Cellectis S.A. (EPA:ALCLS)

Market Cap	87.52M
Revenue (ttm)	47.54M
Net Income (ttm)	-35.51M
Shares Out	72.09M
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	87,250
Average Volume	242,724
Open	1.266
Previous Close	1.260
Day's Range	1.214 - 1.268
52-Week Range	1.140 - 3.025
Beta	3.28
RSI	37.06
Earnings Date	Mar 5, 2025

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UC...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 222
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCLS

Financial Performance

In 2024, Cellectis's revenue was $49.22 million, an increase of 435.37% compared to the previous year's $9.19 million. Losses were -$36.76 million, -63.62% less than in 2023.

Financial numbers in USD